C-BQH0Abliva
orphan drugs, mitochondrial disease
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-BQH0
C-BQH0C-BQH0orphan drugs, mitochondrial disease
0-100 chain-logic scale · 15 dimensions · scored on public evidence
A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects
This will be a double blind, randomised, placebo controlled, single and multiple oral dose study conducted in 3 parts: Part A, Part B and Part C. Part A and Part B include healthy volunteers only and will be completed before Part C including patients with primary mitochondrial disease will be initiated. The starting dose in the first cohort of Part A will be 25 mg. The dose level in the additional cohorts will be decided following review of data of the previous cohorts.
Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors - Hadean Ventures CLICK HERE FOR INVESTOR PORTAL HOME TEAM NEWS PORTFOLIO INVESTORS IMPACT EVENTS CAREERS CONTACT Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors on June 1, 2022 in 2022 , News Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global l … ESTOR PORTAL News June 1, 2022 Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors All News NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, BELARUS, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL REST … ne 9th 2022. Summary of background and use of proceeds The financing will fully fund the commencement of a potentially pivotal/registrational Phase 2/3 study for KL1333 and its progression to the outcome of a key interim analysis which will not only inform as to the size of the remainder of the study, but also provide investors and potential strategic partners with guidance as to the relative chance of eventual success. In addition, the funds will support the preparation of A
Abliva | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Abliva Website: Abliva Business Area(s) Rare Diseases Mitochondria Description Abliva develops mitochondrial medicine. They have one project in clinical phase I (KL1333) for genetic mitochondrial diseases and one project in clinical phase II development for the prevention of moderate to severe trau
16 Mitochondria Companies Worldwide | Biotech Careers Skip to main content Biotech Careers Contact Submit an Employer Contact Add an Employer Search Open main menu Contact Submit an Employer Contact Add an Employer Search Main navigation Careers Job Areas People Articles Videos Biotech Companies Biotech Jobs Business Areas Mitochondria 16 Employers in 18 locations Employers working on Mitochondria work in 20 other areas Displaying 1 - 15 of 20 related areas Show: 15 50 All Therapeutics (3) Rare Diseases (2) Small Molecules (2) Alzheimer's (1) Antisense RNA (1) Cancer Diagnostics (1) Cell
FALCON study: Efficacy of KL1333 in adult patients with primary mitochondrial disease - Cambridge Clinical Mitochondrial Research Group Loading... Menu Menu Search Home Our Research Our Research Clinical Trials Research Studies Patient Resources Clinics Clinical Vision Lab Our staff Our staff Clinical Visitors Previous staff members Work with us News and Events Contact MitoCAMB Donate LifeArc Centre Centre Overview Areas of Focus Centre Staff News Contacts / Clinical Trials / FALCON study: Efficacy of KL1333 in adult patients with primary mitochondrial disease FALCON st
Abliva AB - Executive Leadership | The Org Platform Enrich Pricing Log in Sign up Abliva AB Teams Executive Leadership Unverified Executive Leadership 2 people · 0 jobs This department provides high-level strategic direction and governance for the organization. People ( 2 ) David Laskow-Pooley Chairman Jan Törnell Director of the Board Jobs ( 0 ) No jobs in this team Other teams View all teams Leadership Team 4 people · 0 jobs Research and Development 3 people · 0 jobs Leadership Council 3 people · 0 jobs Company About Contact Blog Business Solutions Trust Pricing Directory Companies People
Abliva's CEO: “One step closer to a marketed medicine” - Biostock Abliva's CEO: “One step closer to a marketed medicine” - Biostock Skip to content Start News TV Event Analytics Premium Premium Content VC Atlas About Us Search Log in Subscribe Search: Close Home / Abliva's CEO: “One step closer to a marketed medicine” Intervju | Publicerad 24 juli, 2024 Abliva’s CEO: “One step closer to a marketed medicine” Abliva has reported positive interim analysis results for the potentially registrational FALCON study, assessing KL1333 in patients with primary mitochondrial disease. While validating the … cuss key aspects of the program, and we look forward to taking advantage of the rolling review of our new drug application when, if the study is successful, we seek approval of our medicine upon completion of this study. Finally, the positive interim analysis has triggered a convertible loan conversion, providing additional proceeds of 42 million SEK before transaction costs. How will the money be used? – The convertible loan conversion completes the financing round of SEK 80
%PDF-1.7 4 0 obj (Identity) endobj 5 0 obj (Adobe) endobj 8 0 obj > stream x�� |U��?>sι�������%7 7�BBr IX@ ��y�AqCť⾷�Z��܀� [�u�m�j�V���� ����9s& ���}�������}�g�̜�g��y�� A!d���̝6%� �.�:�B�}��5�~_T�o��� B���VϘܿi��ݶ !Mޔ�ںC/��.��؉��oS�̞{� -� u!���S�6U �������f��-��W�!�?���w��X�PӁ�:�s��t�����7���_�=�l���;��K�x!]xy��u(��Q�oX =���n B{oF���� ]'f�� ���W@����y��u�՛�;y��@�������ްf��!�UmB(�4������Z�#N� ���8o]�>4����Vwo����E� W���k:Vw���K�� ��6�[�qӐ��� ��m�^g^ p"��8 m��� �T U��K� �O�� R�}�o�V K���8t2��� rP.� !�xx.wy!���;J�-�B(2�J�U��CJ��e � �R[O��'�'t�$��OC�g�
%PDF-1.4 %���� 1 0 obj > endobj 2 0 obj > stream ����JFIF��Adobee���C 4" @.0&4KBONJBIHS^xeSXqZHIh�iq{���Qd�����x�����C =""=�VIV����������������������������������������������������e"�� ���}!1AQa"q2���#B��R��$3br� %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz��������������������������������������������������������������������������� ���w!1AQaq"2�B���� #3R�br� $4�%�&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz������������������������������������������������ … �����������?�uo�T�-> ء,]A ^T�s�ۦ)B�&��#�B�JM/�D�V�{x��ʏ����b�'0F��*8��RFp[��m�s��~����-w� ��^W=qA��rM�;T��58��J�YF�6�}����П�D��=��u�&���A8V�v��n� ߲meHV����S�0:�Mʜ���S��0�` KA H? ��e�A�}��ش�y$���l��Gc���krWi 4b2ğ��jia�Kw�- ʆڦ5��������iJ���=��*�!6�e.�����Rs����S��Zk���e���8��ǯzi�n�/�i�n��h���� �W��� ���iUQ� F5�ߠ�ӄ��koІ4����S �����@������L��O��uͬ7��ݪUGʹ��gl���Q yEQ�v����*j+WJ ݣgN ݢ9�Ia1�/˴�tP��U��ۊ���*J)� �1�6���ȷ;?q ȥW� (=E>��H� ${ 1�c
%PDF-1.7 %���� 1 0 obj >/Metadata 15216 0 R/ViewerPreferences 15217 0 R>> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 10 0 R] /MediaBox[ 0 0 612 792] /Contents 5 0 R/Group >/Tabs/S/StructParents 0>> endobj 5 0 obj > stream x���]sܺ���]����I�d#�H��r�J ���Ļ�Ϧ��� yl�bI�4>Y�_4@�� Q�u�����f | r��vW 7���ٳ���ns�y��xxq��o�߿n�n>]�lvW�7���~���~�n>l����� O�Te�z!����k���n������y��������������'��U�(ZYV�.tەR����yW|�7>�O��~����'�W��o�� �>yn ���?�K j�7xx�O]k���fϣ8;:�Ϝg�.�M{w$�1��:�njz�d�bj�b���*�������~oN_����
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
#euromit #mitochondrialdisease | Magnus Hansson LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and
Abliva AB - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 01 Feb 2026 Abliva AB Subsidiary Company | 2000 | Sweden | < 10 | STO: ABLI | abliva.com Subsidiary Company | 2000 | Sweden | < 10 | STO: ABLI | abliva.com Last update 01 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Nervous System Diseases Endocrinology and Metabolic Disease Small molecule drug Disease domain score A glimpse into the focused therapeutic areas No Data … S and suggesting up to a 100-fold increase in APDS prevalenceSubmitted new drug application for leniolisib for the treatment of APDS in Japan2025 total revenue guidance raised to US$335 million - US$350 million, up from prior US$325 million - US$340 millionOverall cash and marketable securities increased to US$130.8 million at the end of the second quarter 2025 from US$108.9 million at the end of the first quarter 2025, primarily due to cash generated from operationsPharming … dy, or a named patient program. Pediatric label expansion We remain on track to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS in the third quarter of 2025. An approval decision from the FDA is expected in the first half of 2026. Japan In June 2025, we submitted a new drug application (NDA) to the Japanese Pharmaceuticals and Medical Devices Ag … cision from the PMDA is expected in nine months based on priority review of the application, due to orphan drug designation (ODD) granted by the Ministry of Health, Labour and Welfare of Japan (MHLW) for the treatment of APDS. European Economic Area (EEA) We are on track to complete the manufacturing activities requested by the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) as part of the ongoing review of the leniolisib Marketing Authorisatio … (CHMP) as part of the ongoing review of the leniolisib Marketing Authorisation Application (MAA) for APDS patients 12 years of age and older, and to submit a response by the January 2026 deadline. Leniolisib for additional primary immunodeficiencies (PIDs) Two Phase II clinical trials are evaluating leniolisib for additional primary immunodefici
%PDF-1.5 %���� 90 0 obj > endobj xref 90 81 0000000016 00000 n 0000002272 00000 n 0000002380 00000 n 0000003764 00000 n 0000003900 00000 n 0000004399 00000 n 0000004930 00000 n 0000005313 00000 n 0000005349 00000 n 0000005462 00000 n 0000005573 00000 n 0000005662 00000 n 0000006181 00000 n 0000006799 00000 n 0000007934 00000 n 0000008384 00000 n 0000009442 00000 n 0000010316 00000 n 0000011334 00000 n 0000011746 00000 n 0000012774 00000 n 0000013663 00000 n 0000013777 00000 n 0000014729 00000 n 0000015428 00000 n 0000018078 00000 n 0000018153 00000 n 0000018250 00000 n 0000018399 00000 n 00000 … �uS��r�T�����f�s�V� v��o >��� ���Q� �U�! endstream endobj 151 0 obj >stream application/pdf 영진약품_로고 2015-06-10T10:19:15+09:00 2015-06-10T10:19:15+09:00 2015-06-10T10:19:15+10:00 Adobe Illustrator CS6 (Windows) uuid:684235bd-60de-4577-b4bf-b9816c9a0c4a xmp.did:6A44E3B40E0FE5119C14B74A854723CC uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:c6a218eb-1ecd-6b42-bb17-2fe8d9c395b8 xmp.did:0980117407206811822A897E387FE54C uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf save … 9 Adobe PDF library 10.01 endstream endobj 152 0 obj > endobj 153 0 obj >stream application/pdf 영진약품_로고 2015-06-10T10:19:15+09:00 2015-06-10T10:19:15+09:00 2015-06-10T10:19:15+10:00 Adobe Illustrator CS6 (Windows) uuid:684235bd-60de-4577-b4bf-b9816c9a0c4a xmp.did:6A44E3B40E0FE5119C14B74A854723CC uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:c6a218eb-1ecd-6b42-bb17-2fe8d9c395b8 xmp.did:0980117407206811822A897E387FE54C uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf save … &ζ�)a�|>0��OĻ��T�E�Y�S�Yrt�� ��|����Yji��K��(|d�=�0�xn���F��k2�Y >stream application/pdf 영진약품_로고만 2015-06-18T16:20:05+09:00 2015-06-18T16:20:05+09:00 2015-06-18T16:20:05+10:00 Adobe Illustrator CS6 (Windows) uuid:83405542-f165-4e71-be7b-33421fcdb7b3 xmp.did:4F3393D08515E511AAC49B927B827B64 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:684235bd-60de-4577-b4bf-b9816c9a0c4a xmp.did:6A44E3B40E0FE5119C14B74A854723CC uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf sav … 099 Adobe PDF library 10.01 endstream endobj 52 0 obj > endobj 53 0 obj >stream application/pdf 영진약품_로고만 2015-06-18T16:20:05+09:00 2015-06-18T16:20:05+09:00 2015-06-18T16:20:05+10:00 Adobe Illustrator CS6 (Windows) uuid:83405542-f165-4e71-be7b-33421fcdb7b3 xmp.did:4F3393D08515E511AAC49B927B827B64 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uu
Abliva AB Share Price, Forecast & Financials (STO:ABLI) | Stockopedia Home StockRanks™ Platform Insights Research & Discuss Editorial & Community Learn & Improve Webinars & Masterclasses Stockopedia Academy Reviews Pricing Get started Log in Sectors Healthcare Biotechnology & Medical Research Abliva AB ABLI — Abliva AB Share Price SEK0.44 0.00 0.00% Last trade - 00:00 Healthcare Highly Speculative Micro Cap Momentum Trap Market Cap SEK467.94m Enterprise Value SEK435.27m Revenue Quality Value Momentum Stock Rank ™ StockReport™ Accounts Balance sheet Income statement Cash … ) 52w High -2.64% 50d MA +0.55% 200d MA +76.18% Growth & Value 12m Forecast Rolling Industry Market PE Ratio (f) n/a PEG Ratio (f) n/a EPS Growth (f) n/a Dividend Yield (f) n/a Valuation (ttm) Industry Market Price to Book Value 7.59 Price to Tang. Book 9.25 Price to Free Cashflow n/a Price to Sales n/a EV to EBITDA n/a Shareholder Activity Type Buy / Hold / Sell Institutions Directors Community Guru Screens Subscribe to view Quality Name Industry Market Return on Capital
Eskil Elmér - Insider Trades at Abliva AB · Membre du Conseil Skip to content InsiderTrades SIGMA Analysis Recommendations TOP Basket NEW Terminal NEW Companies Executives Performance Blog GB EN GB EN Insiders Trades Sigma InsiderTrades SIGMA Multi-market insider intelligence. Official public filings, re-aggregated and scored. Private beta. FR US DE CH GB CA IT ES NL BE NO FI DK AU AT IE KR IN JP HK + 8 markets Product Recommendations Terminal Companies Insiders Performance Backtest Compare Discover Markets Sectors Top movers Leaderboard Clusters Heatmap Archive Resources Methodology How it wo
Eskil Elmér - CSO at Abliva AB | The Org Platform Enrich Pricing Log in Sign up Abliva AB Eskil Elmér Unverified Eskil Elmér CSO Contact Eskil Elmér, born 1970, is consultant physician and adjunct professor of basal and clinical neurophysiology at Lund University (Sweden) and group leader of the Mitochondrial Medicine lab at the department of Clinical Neurophysiology. Dr Elmér is patentee and co-founder of both Maas Biolab, LLC and Abliva AB (former NeuroVive Pharmaceutical AB), and CSO of Abliva, with overall charge of the company’s pre-clinical research. In addition, Eskil Elmér is a pract
Dr. Eskil Elmer - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Dr. Eskil Elmer CSO & Vice President Discovery at Abliva AB Dr. Eskil Elmer 's Executive Work History Current CSO & Vice President Discovery , CSO & Vice President Discovery Equilar on 11/19/2024 Abliva AB Past To view Dr. Eskil Elmer's complete executive work history, sign up now Dr. Eskil Elmer 's Biography
VD Erik Kinnman - Abliva Follow us: Abliva About Us Contacts Follow us: Share: Subscribe: news.cision.com / Abliva / NeuroVive Pharmaceutical AB Interim Report January - September 2019 / VD Erik Kinnman VD Erik Kinnman Wed, Nov 20, 2019 08:30 CET NeuroVive CEO Erik Kinnman Low resolution Medium resolution Original resolution About Us Abliva – Delivering mitochondrial health Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has
Mitochondria Day 2020 – Abliva Skip to content Abliva Delivering mitochondrial health English English Svenska Abliva This is Abliva Delivering mitochondrial health Orphan Drugs Relevant publications Mitochondrial Disease Primary mitochondrial disease MELAS-MIDD and KSS-CPEO Leigh Syndrome LHON Patients Expanded access policy Research & Development Portfolio KL1333 NV354 Early programs Clinical trials The FALCON Study Contact Privacy policy Search Search Mitochondria Day 2020 On the occasion of The World Mitochondrial Disease Week, Abliva held a virtual Mitochondria Day 2020, on 16 S
Staff change – Abliva Skip to content Abliva Delivering mitochondrial health English English Svenska Abliva This is Abliva Delivering mitochondrial health Orphan Drugs Relevant publications Mitochondrial Disease Primary mitochondrial disease MELAS-MIDD and KSS-CPEO Leigh Syndrome LHON Patients Expanded access policy Research & Development Portfolio KL1333 NV354 Early programs Clinical trials The FALCON Study Contact Privacy policy Search Search Press releases Choose year All 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 All MAR Regulatory 1 February
Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development Social share for Facebook Social share for Twitter/X Social share for LinkedIn Social share for Bluesky Share with Email English Swedish Published: 2021-01-20 20:00:00 CET Abliva AB - Changes board/management/auditors Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the Board of Directo
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage - Hadean Ventures CLICK HERE FOR INVESTOR PORTAL HOME TEAM NEWS PORTFOLIO INVESTORS IMPACT EVENTS CAREERS CONTACT Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage on January 21, 2021 in 2021 , News Abliva appoints Ellen Donnelly as new CEO as they enter a new development stage — Hadean Ventures Home Portfolio Team Impact Investors News Events Careers Contact CLICK HERE FOR INVESTOR PORTAL News January 21, 2021 Abliva appoints Ellen Donnelly as new CEO as they enter a new develop
J.P. Morgan Healthcare Conference – Abliva Skip to content Abliva Delivering mitochondrial health English English Svenska Abliva This is Abliva Delivering mitochondrial health Orphan Drugs Relevant publications Mitochondrial Disease Primary mitochondrial disease MELAS-MIDD and KSS-CPEO Leigh Syndrome LHON Patients Expanded access policy Research & Development Portfolio KL1333 NV354 Early programs Clinical trials The FALCON Study Contact Privacy policy Search Search « All Events This event has passed. J.P. Morgan Healthcare Conference 8 January, 2024 - 11 January, 2024 «
News – Page 22 – CheckOrphan Skip to content --> Home About Us Log In Top Menu --> --> --> News All News Finance Treatment People Research Videos Treatments Clinical Trials Access Programs About Access Programs Diseases Events Networks Research Main Menu × Subscribe for Free Newsletter Join Now --> --> Signup for Our Newsletter --> Email * Type * Supporter Researcher Physician Patient Medical Student Medical Industry --> * Required Field Email Marketing Services by Benchmark Close --> × Generate RSS Select number of items 10 25 50 100 Generate RSS Close Home / News / Pa
%PDF-1.4 %���� 9641 0 obj > endobj xref 9641 17 0000000016 00000 n 0000003300 00000 n 0000003463 00000 n 0000005437 00000 n 0000007394 00000 n 0000007921 00000 n 0000008473 00000 n 0000008598 00000 n 0000008723 00000 n 0000045739 00000 n 0000045780 00000 n 0000045859 00000 n 0000046174 00000 n 0000054256 00000 n 0000401346 00000 n 0000002959 00000 n 0000000654 00000 n trailer ]/Prev 4535568/XRefStm 2959>> startxref 0 %%EOF 9657 0 obj >stream h��WyTSW�^6V��Pb� ��ƨ�AK Jİ4T4T� *��VW���a0E@tDA��E�At� V�cQiG���G�=g��wNNr��~��7 �ۀ �ƃ�,0��\̶��c��mzMI���0���'��0�[��_�o� ��c�[ … �Ʊ;�ٜ��G o�����C����C7^-�ݥ�� > endobj 9648 0 obj > endobj 9649 0 obj >stream application/postscript Utskrift Martin Olsson 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 xmp.did:e71fd692-22c4-2b49-a945-88e9ca718ed0 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:76c386df-ac92-6840-8abd-24ebb0c9bcfa xmp.did:76c386df-ac92-6840-8abd-24ebb0c9bcfa uuid:5D20892493 … ab6 2020-05-25T14:25:42+02:00 Adobe Illustrator 24.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:2e4c0b70-c8fa-b24f-bf98-d4b2a4884235 2020-05-25T14:45:22+02:00 Adobe Illustrator 24.1 (Windows) / saved xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) / Print False False 1 297.000000 210.000000 Millimeters Cyan Magenta Yellow Black Standardfärgrutegrupp 0 Vit CMYK PRO … :efefab2d-c8db-11ee-0000-a37a38f25e19 uuid:efefab2d-c8db-11ee-0000-a37a38f25e19 application/pdf Microsoft PowerPoint - 2024_01_11_Abliva_Pipeline_white_green Martin Olsson endstream endobj 23 0 obj > endobj 24 0 obj >/PageTransformationMatrixList >/PageUIDList >/PageWidthList >>>>>/Resources >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageC/ImageI]/Properties >/XObject >>>/Rotate 0/StructParents 8/TrimBox[0.0 0.0 841.89 595.276]/Type/Page>> endobj 25 0 obj >stream H��Wi� ��� - … :efefab2d-c8db-11ee-0000-a37a38f25e19 uuid:efefab2d-c8db-11ee-0000-a37a38f25e19 application/pdf Microsoft PowerPoint - 2024_01_11_Abliva_Pipeline_white_green Martin Olsson endstream endobj 39 0 obj > endobj 40 0 obj >stream GPL Ghostscript 9.06 2024-02-08T13:49:03+01:00 2024-02-08T13:49:03+01:00 PScript5.dll Version 5.2.2 uuid:efefab2d-c8db-11ee-
A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease ClinicalTrials.Veeva Search CTV Search for a location Search for trials trials Find clinical trials Close Menu Share Share trial Follow Follow trial A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease A Abliva Status and phase Completed Phase 1 Conditions MELAS Syndrome Mitochondrial Myopathies Mitochondrial Respiratory Chain Deficiencies Mitochondrial Diseases Treatments Drug: Placebo Oral Tablet Drug: KL1333 Study type
Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Ce … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease July 18, 2024 | 5 min read Twitter LinkedIn Facebook Email Print - Independent committee confirms FALCON study is powered for potential success with both alternative endpoints pa … lick here . If you would like to ask a question during the live Q&A, please submit your request to [email protected] . About the FALCON Trial FALCON is a Phase 2, global, randomized, placebo-controlled, potentially registrational trial evaluating the safety and efficacy of KL1333 in adult patients with primary mitochondrial disease who experience consistent, debilitating fatigue and myopathy. Patients with mitochondrial DNA mutations who meet the eligibility c … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Cerevance to Present During the 6th Annual LSX World Congress USA - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Cerevance to Present During the 6th Annual LSX World Congress USA September 6, 2023 | 2 min read Twitter LinkedIn Facebook Email Print Cerevance today announced Craig Thompson, chief executive officer (CEO) and Johnna Simões, vice president, corporate development, will participate in panel discussions during th … bsp; 2 min read · Tristan Manalac Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst China BIO 2026: US needs to dodge China’s ‘inescapable dependencies’ to protect biotech June 24, 2026 · 2 min read · Annalee Armstrong BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kin … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Abliva AB (publ) (NEVPF) Stock Price, News & Analysis Skip to main content Research Tools All Access Research Tools Live News Feed Momentum Alerts Idea Engine Export Data (CSV) See All Research Tools My MarketBeat My Portfolio My Newsletter My Account Calculators Dividend Calculator Dividend Yield Calculator Market Cap Calculator Options Profit Calculator Stock Average Calculator Stock Split Calculator Stock Profit Calculator Stock Screeners Stock Screener ETF Screener Stock Ratings Screener Dividend Screener Earnings Screener Updated Insider Trades Screener Updated Trending Stocks Trendin … r Abliva AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS Terms SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including t … be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page . Read our full terms of servi … 2,000% run and has identified the top... InvestorPlace | Sponsored The $15 Gold Fund That Pays Up to $1,152/Month Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying... Investors Alley | Sponsored Do NOT Buy SpaceX – Do This Instead SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul... Stansberry Research | Sponsored Are we ignoring the same signal Wall Stree … te is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Featured By Empowering Individual Investors 345 N Reid Place, Suite 620, Sioux Falls, SD 57103 [email protected] (844) 978-6257 Twitter Facebook YouTube LinkedIn Instagram TikTok About MarketBeat About Editorial Guidelines Authors Press Room Careers Contac
Industry Advisory Council Leadership - UMDF Mitochondrial Disease Resources Medications Insurance Assistance Forzinity Kygevvi Get Involved Research About Us About Us 2026-2029 Strategic Plan 2025 Annual Report Donate Donate Now Energy for Life Family Tribute Pages Match Your Gift Get Support Select Page Industry Advisory Council Magnus Hansson, MD, PhD • Chair Dr. Hansson accepted the position of co-chair to the UMDF’s Industry Advisory Council (IAC) in 2025. Magnus is Executive Medical Director and KL1333 Global Program Team Lead for Abliva, A Member of Pharming Group. He received his Medica
%PDF-1.4 %���� 3997 0 obj > endobj xref 3997 28 0000000016 00000 n 0000002389 00000 n 0000002552 00000 n 0000004957 00000 n 0000005408 00000 n 0000005802 00000 n 0000005852 00000 n 0000006343 00000 n 0000007158 00000 n 0000007273 00000 n 0000007359 00000 n 0000007826 00000 n 0000008370 00000 n 0000011402 00000 n 0000011458 00000 n 0000011583 00000 n 0000012327 00000 n 0000012368 00000 n 0000013112 00000 n 0000013153 00000 n 0000023185 00000 n 0000741231 00000 n 0000745093 00000 n 0000747250 00000 n 0000752597 00000 n 0000766154 00000 n 0000002132 00000 n 0000000873 00000 n trailer ]/Prev 32239 … y�k��Ub �{�GS_�sN�6 a������ջ�]�ϊ�Rqӯ�Ak��a Ƽ�u�9@#��&� ��r�����-$�`�@ Lrfp��P�|��[���m�c���ce,���>D�v �g�`1EOк�py��G=���@���n :#(�rYh#@3 ��B��-h��#Tʩ1�1ǩ��[8t��IS�lX�6�A� t��d��@��1M�$���r�m����_�U�m�.I� �f)�!ފ���&(:Hܺ��=��)K��� ȴ,�| � ���nW�;��� _���%I�������}?´&*������v��"F���j�6�����ű+���h�ι�B���Ԛ�5#�����(u]�pq�9��0[�\��z��$����%�a��?�j����r��m�崜Z[��C����e12Q��OM��5�A_ C�����_ ���搊-բ-u�\$��Q�t�j��3=�36��%�tu��ZL���s�}m0�"? b�� … ���=�AOo����� ѿhyآ endstream endobj 169 0 obj > endobj 170 0 obj >stream application/postscript Utskrift Martin Olsson 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 xmp.did:e71fd692-22c4-2b49-a945-88e9ca718ed0 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:76c386df-ac92-6840-8abd-24ebb0c9bcfa xmp.did:76c386df-ac92-6840-8abd-24ebb0c9bcfa uuid:5D20892493 … ab6 2020-05-25T14:25:42+02:00 Adobe Illustrator 24.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:2e4c0b70-c8fa-b24f-bf98-d4b2a4884235 2020-05-25T14:45:22+02:00 Adobe Illustrator 24.1 (Windows) / saved xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) / Print False False 1 297.000000 210.000000 Millimeters Cyan Magenta Yellow Black Standardfärgrutegrupp 0 Vit CMYK PRO … 0 Adobe PDF library 10.01 endstream endobj 171 0 obj > endobj 172 0 obj >stream application/postscript Utskrift Martin Olsson 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 xmp.did:e71fd692-22c4-2b49-a945-88e9ca718ed0 uuid:5D20892493BFDB11
Privacy policy – Abliva Skip to content Abliva Delivering mitochondrial health English English Svenska Abliva This is Abliva Delivering mitochondrial health Orphan Drugs Relevant publications Mitochondrial Disease Primary mitochondrial disease MELAS-MIDD and KSS-CPEO Leigh Syndrome LHON Patients Expanded access policy Research & Development Portfolio KL1333 NV354 Early programs Clinical trials The FALCON Study Contact Privacy policy Search Search Privacy policy Abliva AB (publ), reg. no 556595-6538 (“Abliva”) is committed to protect and respect your privacy. By way of this privacy n … ur business operations, e.g. via newsletters, • To receive and process your job application, • To comply with legal obligations and • To establish and defend legal claims. In the tables below, we inform more in detail about our processing of your personal data including the legal basis for the processing. To provide and manage our website We process your personal data to provide you with a functioning website and understand how visitors use the website. We collect information … ights, see Your rights as a data subject below. To receive and process your job application We, or a recruiter engaged by us, process your personal data when you have submitted a job application to us or to a recruiter in order to evaluate and determine whether you might be a suitable candidate for a position at Abliva. Categories of personal data: Legal basis: • Contact information. • Curriculum vitae. • Personal statement. • References. • Other personal data whi … ement. • References. • Other personal data which may be disclosed by you in the application. We process your personal data based on our legitimate interest of being able to manage our business by processing personal data in the context of recruitment matters, which overrides your interest of protecting your personal data. To comply with legal obligations We process your personal data to verify your individual identity when you contact us for example to exercise your rights as
%PDF-1.5 %���� 8234 0 obj > endobj 8258 0 obj >/Filter/FlateDecode/ID[ ]/Index[8234 67]/Info 8233 0 R/Length 121/Prev 1352071/Root 8235 0 R/Size 8301/Type/XRef/W[1 3 1]>>stream h�bbd```b``1� �ID���H�e �[D���N��S�l�,/�l�����ǁM��?$ ց� M ��p ɔ� ��"o�_���v����8��� �n��� endstream endobj startxref 0 %%EOF 8300 0 obj >stream h�b```�� � b� � ��ea�X�"�: 0(r��� �:V�\D���qp?�����tlA��J�� ք�/�ߖ�nh�+i``X��mw�ıYٯ��ݽ��f���� �UŤ5� r�� G�� ��M og�T���6���/�CE `�gs�R�+�q(�A9�������* ����������n`�� �``�bq �E��Al�2���P�mlb��4�U�̀����� ;`X�0Y�i1 � �:� Cuc�� … d 2013 2020-12-01T12:02:04+01:00 2020-12-01T12:02:04+01:00 Microsoft® Word 2013 application/pdf uuid:705ee5a1-8d8a-8948-b6ad-5216503e0275 uuid:1d6eb283-3618-4d45-8184-77f8260c445b endstream endobj 138 0 obj >stream h�,�1 �0C����_� .�."n� X�E���핦KI��ʨ���� �t��ar�ş*�j��L 4����N�3�CET"�K_,;!S�vBf �� ���~�|h�O��t'G endstream endobj 139 0 obj >stream h026V0P���w.JM,���sI,I�p�2204703�4�4232�҄��i�f&�秕�S�/JQ*4����O�k��!�a�m`�n`��� P��R���C�� @���'� endstream endobj 1
Abliva - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corpor … latforms for targeted drug delivery systems $55.5M Daxing Industrial Investment Fund , Beijing Medical and Health Industry Investment Fund ... Read more 49/100 5th Curemark 2004 , New York City ( United States ) , Series B Developer of therapeutics for the treatment of Autism and other neurological diseases $96M Grimley Capital , Springboard Enterprises & 1 others 49/100 6th Connecta Therapeutics 2018 , Barcelona ( Spain ) , Seed Developer of drugs for treating neurologic
Symposium - 2021 - UMDF Mitochondrial Disease Resources Medications Insurance Assistance Forzinity Kygevvi Get Involved Research About Us About Us 2026-2029 Strategic Plan 2025 Annual Report Donate Donate Now Energy for Life Family Tribute Pages Match Your Gift Get Support Select Page Mitochondrial Medicine Symposium PLEASE NOTE: You’ve reached a page relating to Mitochondrial Medicine 2021. For the latest news on the current year’s event, please visit umdf.org/symposium/ . About Mitochondrial Medicine Symposium Each Year, UMDF’s Mitochondrial Medicine Symposium brings together the
Abliva AB | BIO-Europe You need to enable JavaScript to run this app. This site is part of the Informa Connect Division of Informa PLC Informa PLC About Us Investor relations Talent This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067. November 9–11, 2026 Koelnmesse Cologne, Germany Home home Ways to attend expand_more Registration Options Company Presentation Options Delegations Program expand_more 2026 Agenda Agenda In
%PDF-1.4 %���� 365 0 obj > endobj xref 365 19 0000000016 00000 n 0000002870 00000 n 0000003003 00000 n 0000003047 00000 n 0000003861 00000 n 0000003975 00000 n 0000004087 00000 n 0000006148 00000 n 0000006571 00000 n 0000007105 00000 n 0000007541 00000 n 0000007820 00000 n 0000008382 00000 n 0000008656 00000 n 0000017065 00000 n 0000027787 00000 n 0000064800 00000 n 0000064839 00000 n 0000000676 00000 n trailer ]/Prev 3932442>> startxref 0 %%EOF 383 0 obj >stream h��Wkl[g~��˱s�� _��� �8qҤ�4M ��q�vk֬���͚�k |���IF7;K7�"C�V���˸J �L�JLhe�4H�"�ʆJTL�� ;>�� H��,�������y�wN袠��+`yـ�7��M� … [�W�p6S�La�l��3�`m&\fpW�7�J����zB�� w=�d�x���.s�˝Mnd����Ʌ������^��� >stream application/postscript Utskrift Martin Olsson 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 xmp.did:e71fd692-22c4-2b49-a945-88e9ca718ed0 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:76c386df-ac92-6840-8abd-24ebb0c9bcfa xmp.did:76c386df-ac92-6840-8abd-24ebb0c9bcfa uuid:5D20892493 … ab6 2020-05-25T14:25:42+02:00 Adobe Illustrator 24.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:2e4c0b70-c8fa-b24f-bf98-d4b2a4884235 2020-05-25T14:45:22+02:00 Adobe Illustrator 24.1 (Windows) / saved xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) / Print False False 1 297.000000 210.000000 Millimeters Cyan Magenta Yellow Black Standardfärgrutegrupp 0 Vit CMYK PRO … ϟ� WH�[�Fr?{�! > endobj 20 0 obj >stream H�\��n� �� > endobj 22 0 obj >stream application/postscript Utskrift Martin Olsson 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 2020-05-25T14:49:29+02:00 Adobe Illustrator 24.1 (Windows) xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 xmp.did:e71fd692-22c4-2b49-a945-88e9ca718ed0 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:76c386df-ac92-6840-8abd-24ebb0c9bcfa xmp.did:76c386df-ac92-6840-8abd-24ebb0c9bcfa uuid:5D20892493 … ab6 2020-05-25T14:25:42+02:00 Adobe Illustrator 24.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:2e4c0b70-c8fa-b24f-bf98-d4b2a4884235 2020-05-25T14:45:22+02:00 Adobe Illustrator 24.1 (Windows) / saved xmp.iid:e71fd692-22c4-2b49-a945-88e9ca718ed0 2020-05-25T14:49:29+02:00 Adobe Illustrator 2
%PDF-1.5 %���� 9227 0 obj > endobj 9245 0 obj >/Filter/FlateDecode/ID[ ]/Index[9227 28]/Info 9226 0 R/Length 92/Prev 4857901/Root 9228 0 R/Size 9255/Type/XRef/W[1 2 1]>>stream h�bbd``b`� 3��"�`� [A�@�k�� $xn � ! R"$D�����+�P� bU��% L�*�@&30 ��}� �� 3 endstream endobj startxref 0 %%EOF 9254 0 obj >stream h��U�O[U����o����Bò/ &.0�EG퀱@Rl�ZlK[��]a*�5ni�J�/�F��*#Q�_�3���蒉Ɇf�|3�2f�E �-���m�|�;��sϗ�9��]�"�@l2�ydH�� � ����)�@#=�}�?_������ޒ��^Xe���!Q��x�U�_K��/v~�va�p �~L Dй��w�]a=����(��C|Ѩ����g!ٟ��� ��6{.*�L ���X "��c��£Ыb/4 �����~&҉> … ~%\1�%2\�*.�����[��u�k ����ǔ��T��_�K� endstream endobj 9244 0 obj >stream application/postscript NeuroVive_Original_CMYK Adobe Illustrator CS2 2008-06-27T08:07:57+02:00 2008-07-03T14:47:06+02:00 2008-07-03T14:47:06+02:00 256 92 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f&#x … �R� �� - *���p+�)B,p[6HW(����,h� 0(sY� endstream endobj 32 0 obj >stream application/pdf Utskrift 2013-12-13T16:02:43+01:00 2013-12-13T16:02:43+01:00 2013-12-09T13:41:05+01:00 Adobe Illustrator CC (Macintosh) 256 116 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8f … GB PROCESS 130 54 140 Adobe PDF library 10.01 endstream endobj 33 0 obj >stream application/pdf Utskrift 2013-12-13T16:02:43+01:00 2013-12-13T16:02:43+01:00 2013-12-09T13:41:05+01:00 Adobe Illustrator CC (Macintosh) 256 116 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8f … 11T12:07:49+01:00 Adobe Photoshop CC (Macintosh) / converted from image/jpeg to application/vnd.adobe.photoshop derived converted from image/jpeg to application/vnd.adobe.photoshop saved xmp.iid:f3438a7f-0ddc-4649-9d15-a755ff1aab9b 2013-12-11T12:07:49+01:00 Adobe Photoshop CC (Macintosh) / saved xmp.iid:09f8673a-5d55-4f46-be16-4214b83b01c8 2013-1
Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent | Pharming Skip to main content Our news Careers Contact us Our company Rare community Advancing rare care Life at Pharming Investors Home Our news Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent Financial results February 20, 2025 Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent On December 15, 2024, Pharming Technologies B.V. (“Pharming”), a wholly-owned subsidiary of Pharming Group N.V., announced a recommended cash offer to t
Mitochondrial Medicine (Virtual Conference) — 20201130 – Wellcome Connecting Science courses and conferences Skip to main content Our events Back Our events Conferences Courses COG-Train Programme Global Training Online courses Past events Your digital mentor podcast Accessibility information FAQ About us Back About us The team Our facilities Wellcome Connecting Science Financial support Health and Wellbeing Guidelines Global Training Impact Stories Accessibility information How to find us News Back News Conferences Courses General Online Courses Press releases Your Digital … of countries here ). If you are in need of financial support and would like to apply for a bursary, please contact the conference organiser . When applying for a bursary you will be asked to provide a letter stating financial need and a CV. Log in details for the virtual conference portal will be provided on Thursday before the event. Abstracts Abstracts We welcome abstracts from all areas relevant to the main themes of the meeting, for both oral and poster presentations. Se … re your abstract is submitted correctly. All abstracts must be submitted by the deadline. If you are intending to submit more than one abstract, please contact the conference organiser prior to registration. The scientific programme committee will assess your abstract after the deadline has passed and you will be notified whether you have been selected for an oral or poster presentation. All those selected for a poster presentation will be given the opportunity to upload a sh … e given the opportunity to upload a short video describing their work. Abstract deadline: 6 October 2020 How to upload an abstract once you have already completed registration: Log back into your registration account using either Firefox or Internet Explorer as your browser, via link above the ‘Share’ button on the right hand column of this page Click on ‘Account’ (top right). Then click on ‘View account history’. This will show a table of … ondrial Medicine 2019 Back to top Registration and deadlines Deadlines Abstract deadline Closed Registration deadline Closed Questions Email the organiser +44 (0)1223 495100 Funded by: Wellcome Hashtag: #MitoMed20 Share Copy this link: Connect with us on Facebook (will open in a new window) Watch our videos on Youtube
Forum: Pharming » Pharming december 2024 » Pagina: 196 Naar hoofdinhoud Ontvang nu dagelijks onze kooptips! word abonnee Van beleggers voor beleggers Inloggen E-mailadres: Wachtwoord: Onthoud mijn inloggegevens Geen account? Registreer gratis Wachtwoord vergeten? Creëer uw eigen portefeuilles en watchlist Ontvang het laatste beursnieuws in uw mailbox Praat en discussieer met ons mee op het forum Uitgebreid zoeken Zoek op Instrument/ISIN Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re … 410 Arcadis 251 10.760 Arcelor Mittal 2.024 322.709 Archos 1 1 Arcona Property Fund 1 310 arGEN-X 18 12.309 Aroundtown SA 1 251 Arrowhead Research 5 10.012 Ascencio 1 45 ASIT biotech 2 697 ASMI 4.101 41.079 ASML 1.763 136.975 ASR Nederland 22 4.740 ATAI Life Sciences 1 7 Atenor Group 1 556 Athlon Group 120 176 Atos 4 4.967 Atrium European Real Estate 2 199 Auplata 1 55 Avantium 36 18.952 Axsome Therapeutics 1 177 Azelis Group 2 123 Azelis Group NV 2 206 Azerion 7 4.363 Bekij … Kliko groeit door met abonnementen 29 mei Partnercontent Het Fresh Fixed Income Fund wint vijf awards in drie jaar 26 mei Partnercontent Analyse: AI-rally rust steeds meer op echte winstgroei 21 mei Partnercontent Beleggen in crypto-ETP's 21 mei Partnercontent Nieuwe generatie beleggers vraagt om nieuwe generatie platformen: Webull kiest Nederland als Europese springplank Gesponsorde links Fintessa Vraag het de winnaar. Uw vermogen verdient Fintessa! De aandelen die wij (niet
Abliva raise awareness of mitochondrial diseases - Biostock Abliva raise awareness of mitochondrial diseases - Biostock Skip to content Start Nyheter TV Event Analytics Premium Premium Content VC Atlas Om Oss Sök Logga in Prenumerera Sök efter: Stäng Hem / Abliva raise awareness of mitochondrial diseases Intervju | Publicerad 4 juli, 2021 Abliva raise awareness of mitochondrial diseases Last week, World Mitochondrial Disease Week took place with events around the world aimed at raising awareness and knowledge about mitochondrial diseases. These diseases are rare and treatment options are scarc
The second quarter report of the year shows strong clinical development for Abliva - Biostock The second quarter report of the year shows strong clinical development for Abliva - Biostock Skip to content Start News TV Event Analytics Premium Premium Content VC Atlas About Us Search Log in Subscribe Search: Close Home / The second quarter report of the year shows strong clinical development for Abliva | Published August 24, 2021 The second quarter report of the year shows strong clinical development for Abliva Abliva's lead clinical program KL1333, aimed at treating primary mitochondrial diseas … bute to reducing risk in the KL1333 clinical program as the company prepares to submit a clinical trial application to initiate a pivotal Phase II/III study. CEO comments BioStock contacted Donnelly to get her thoughts on the report. Ellen K. Donnelly, CEO of Abliva Ellen Donnelly, in Q2, Abliva reached important clinical milestones in preparation for a phase II/III study. What are the next milestones for Abliva and the KL1333 program before initiating the next stage of devel
IP Group set to receive £13.8m from two portfolio company offers - UK Investor Magazine --> --> --> --> --> --> --> --> --> --> Facebook Instagram Linkedin Twitter Vimeo Home Single Company Reports Investment Trust Centre Market Reports & Share Ideas Members Events News Shares Features Commodities/FX Private Equity & Venture Capital Tax-Efficient Guides Property Podcasts Video Awards Account Login Become Member Search Facebook Instagram Linkedin Twitter Vimeo Become Member Login Account Search Home Premium Reports Market Reports & Share Ideas News Funds & Trusts Commodities &
#InvestTalks ⎮ Ellen Donnelly VD Abliva - Invest Talks - Content Relations Sverige Följ oss: Invest Talks - Content Relations Sverige Om oss Följ oss: Dela: Prenumerera: news.cision.com / Invest Talks - Content Relations Sverige / #InvestTalks Podcast ⎮ Ellen Donnelly VD Abliva (ABLI) / #InvestTalks ⎮ Ellen Donnelly VD Abliva #InvestTalks ⎮ Ellen Donnelly VD Abliva tor, jul 07, 2022 11:15 CET Fotograf: #InvestTalks ⎮ Ellen Donnelly VD Abliva #InvestTalks ⎮ Ellen Donnelly VD Abliva Lågupplöst Medelupplösning Originalupplösning Om oss #InvestTalks | Aktuella Vd-inte
#InvestTalks Podcast ⎮ Ellen Donnelly VD Abliva (ABLI) - Invest Talks - Content Relations Sverige Följ oss: Invest Talks - Content Relations Sverige Om oss Följ oss: Dela: Prenumerera: news.cision.com / Invest Talks - Content Relations Sverige / #InvestTalks Podcast ⎮ Ellen Donnelly VD Abliva (ABLI) Svenska #InvestTalks Podcast ⎮ Ellen Donnelly VD Abliva (ABLI) tor, jul 07, 2022 11:15 CET Report this content Abliva avancerar på flera fronter med sina världsunika kandidater för behandling av mitokondriella sjukdomar Intervjun publiceras även i #Investtalks &
%PDF-1.6 %���� 9778 0 obj > endobj 9801 0 obj >/Filter/FlateDecode/ID[ ]/Index[9778 37]/Info 9777 0 R/Length 114/Prev 2116685/Root 9779 0 R/Size 9815/Type/XRef/W[1 3 1]>>stream h�bbd```b`` � 9 �9L~�l�`�!�d &[��Tɲ�w�� "��A$S �dt�� �l���Կ$ ��9�$k8��_3V2012� ����"�?Ý�_ ��^ endstream endobj startxref 0 %%EOF 9814 0 obj >stream h��S�Ka���;�k�2 0�� J¹5�ΐgp�u �? "q)t�J�$����fc�l�b����6�d"F"��B*f0� ����,�J��,b�# C����j��"&�J�vɂ��aZ�ET�i\(5V5.`����+"vґ(''r E.X�H� R]Ċ0��_~9�?������M��#���>j���* � c�7�"�nC��.Ѓ ����t(� � ��Z�5綽j.�i\�����/:�L�a �\��O�1�%ٓ�!� … P�c�.����h� 2_s��bԑ���4��.���8��S�% �\ endstream endobj 9796 0 obj >stream application/postscript NeuroVive_Original_CMYK Adobe Illustrator CS2 2008-06-27T08:07:57+02:00 2008-07-03T14:47:06+02:00 2008-07-03T14:47:06+02:00 256 92 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f&#x … 583A9 uuid:80F98C94FB40DD118C59F2541EC583A9 endstream endobj 9797 0 obj >stream application/postscript Logotype_Sedermera_fondkommission_CMYK_original Adobe Illustrator CS2 2008-06-18T14:27:05+02:00 2008-07-02T13:14:57+02:00 2008-07-02T13:14:57+02:00 256 104 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBw … eam H�\��j�@��>� �C��MA�b��?���NR�Ye5��}g��*�~�3���E�+]7����Mœ9u�� >stream application/postscript NeuroVive_Original_CMYK Adobe Illustrator CS2 2008-06-27T11:36:43+02:00 2008-06-27T11:36:43+02:00 2008-06-27T11:36:43+02:00 256 84 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f&#x … E2B7B5 uuid:5F1646630F44DD119AB7891F60E2B7B5 endstream endobj 204 0 obj >stream application/postscript Logotype_Sedermera_fondkommission_CMYK_original Adobe Illustrator CS2 2008-06-18T14:27:05+02:00 2008-07-02T13:14:57+02:00 2008-07-02T13:14:57+02:00 256 104 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQB
Abliva – Delivering mitochondrial health Skip to content Abliva Delivering mitochondrial health English English Svenska Abliva This is Abliva Delivering mitochondrial health Orphan Drugs Relevant publications Mitochondrial Disease Primary mitochondrial disease MELAS-MIDD and KSS-CPEO Leigh Syndrome LHON Patients Expanded access policy Research & Development Portfolio KL1333 NV354 Early programs Clinical trials The FALCON Study Contact Privacy policy Search Search This is Abliva Delivering mitochondrial health Research & Development About us Abliva Our studies The FALCON Study Pr
Abliva AB - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 01 Feb 2026 Abliva AB Subsidiary Company | 2000 | Sweden | < 10 | STO: ABLI | abliva.com Subsidiary Company | 2000 | Sweden | < 10 | STO: ABLI | abliva.com Last update 01 Feb 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Other Diseases Nervous System Diseases Endocrinology and Metabolic Disease Small molecule drug Disease domain score A glimpse into the focused therapeutic areas No Data … S and suggesting up to a 100-fold increase in APDS prevalenceSubmitted new drug application for leniolisib for the treatment of APDS in Japan2025 total revenue guidance raised to US$335 million - US$350 million, up from prior US$325 million - US$340 millionOverall cash and marketable securities increased to US$130.8 million at the end of the second quarter 2025 from US$108.9 million at the end of the first quarter 2025, primarily due to cash generated from operationsPharming … dy, or a named patient program. Pediatric label expansion We remain on track to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for leniolisib for the treatment of children aged 4 to 11 years diagnosed with APDS in the third quarter of 2025. An approval decision from the FDA is expected in the first half of 2026. Japan In June 2025, we submitted a new drug application (NDA) to the Japanese Pharmaceuticals and Medical Devices Ag … cision from the PMDA is expected in nine months based on priority review of the application, due to orphan drug designation (ODD) granted by the Ministry of Health, Labour and Welfare of Japan (MHLW) for the treatment of APDS. European Economic Area (EEA) We are on track to complete the manufacturing activities requested by the European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) as part of the ongoing review of the leniolisib Marketing Authorisatio … (CHMP) as part of the ongoing review of the leniolisib Marketing Authorisation Application (MAA) for APDS patients 12 years of age and older, and to submit a response by the January 2026 deadline. Leniolisib for additional primary immunodeficiencies (PIDs) Two Phase II clinical trials are evaluating leniolisib for additional primary immunodefici
%PDF-1.4 %���� 415 0 obj > endobj xref 415 41 0000000016 00000 n 0000003253 00000 n 0000003374 00000 n 0000003418 00000 n 0000003919 00000 n 0000004033 00000 n 0000005185 00000 n 0000006171 00000 n 0000006973 00000 n 0000007704 00000 n 0000008466 00000 n 0000008571 00000 n 0000009152 00000 n 0000009865 00000 n 0000010527 00000 n 0000010614 00000 n 0000011971 00000 n 0000012166 00000 n 0000013476 00000 n 0000014594 00000 n 0000015658 00000 n 0000016829 00000 n 0000017944 00000 n 0000023271 00000 n 0000029732 00000 n 0000029810 00000 n 0000029889 00000 n 0000029986 00000 n 0000030135 00000 n 000 … +��:� endstream endobj 444 0 obj > endobj 445 0 obj > endobj 446 0 obj >stream application/pdf NeuroVive logotyp CMYK 2016-03-08T14:35:13+01:00 2016-03-08T14:35:13+01:00 2016-01-23T01:47:40+01:00 Adobe Illustrator CC 2015 (Macintosh) uuid:034e8faf-5f55-2e4c-b8ac-7b8b8c5b6878 xmp.did:09b1249c-d700-43ad-877b-8c63577e22c6 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:7be51674-2986-40ec-9cb8-4227f7a5ce61 xmp.did:7be51674-2986-40ec-9cb8-4227f7a5ce61 uuid:5D20892493BFDB1 … 0 Adobe PDF library 15.00 endstream endobj 447 0 obj > endobj 448 0 obj >stream application/postscript Print Mikael Zethelius 2013-11-22T14:47:27+01:00 2013-11-22T14:47:27+01:00 2013-11-22T14:47:27+01:00 Adobe Illustrator CS6 (Macintosh) xmp.iid:F77F117407206811822A936C5858582E xmp.did:F77F117407206811822A936C5858582E uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf xmp.iid:01801174072068118C1494B09C1A222F xmp.did:01801174072068118C1494B09C1A222F uuid:5D20892493BFDB11914A8590D … 1494B09C1A222F 2011-02-01T16:19:55+01:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:F77F117407206811822A936C5858582E 2013-11-22T14:47:27+01:00 Adobe Illustrator CS6 (Macintosh) / Print False False 1 14.141083 9.975618 Millimeters PANTONE 289 C Default Swatch Group 0 White CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Black CMYK PROCESS 0.000000 0.000000 0.000000 100.000000 CMYK Red CMYK PROCESS 0.000000 … ƃ��/ L�p��eP�"��%�4�D� endstream endobj 118 0 obj > endobj 119 0 obj >stream application/pdf 20150504_Neurovive-status-produkter 2016-03-21T17:26:13+01:00 2016-03-21T17:26:13+01:00 2016-03-01T16:23:05+01:00 Adobe Illustrator CC 2015 (Macintosh) uuid:66558d71-a8ee-6340-bf74-78532a774273 xmp.did:82fcfe04-4485-46fc-9d52-6aab525ba452 uuid:5D208924
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.26.1 BUSINESS COMBINATIONS AND ACQUISITIONS OF NON-CONTROLLING INTERESTS 12 Months Ended Dec. 31, 2025 Disclosure of detailed information about business combination [abstract]   BUSINESS COMBINATIONS AND ACQUISITIONS OF NON-CONTROLLING INTERESTS BUSINESS COMBINATIONS AND ACQUISITIONS OF NON-CONTROLLING INTERESTS Acquisition of Abliva AB On February 14, 2025, the Group acquired 88.9% of the voting shares of Abliva AB (“Abliva”), a listed company based in Sweden. Abliva is a biotechnology company, based in Lund, Sweden, focused on developing
Help us welcome,... - United Mitochondrial Disease Foundation Facebook Log In United Mitochondrial Disease Foundation's Post United Mitochondrial Disease Foundation May 26, 2025 · Shared with Public Help us welcome, ABLIVA - a member of Pharming Group, silver sponsor for this year's Mitochondrial Medicine Conference! Thank you for prioritizing the #mito patient community and helping us build the best #MitoMed Conference in St. Louis. Learn more about our generous sponsors at umdfconference.org/2025-sponsors All reactions: 3 1 share Like Comment
%PDF-1.4 %���� 6463 0 obj > endobj xref 6463 45 0000000016 00000 n 0000002629 00000 n 0000002972 00000 n 0000003402 00000 n 0000003573 00000 n 0000003749 00000 n 0000003882 00000 n 0000004310 00000 n 0000004339 00000 n 0000004945 00000 n 0000005193 00000 n 0000005837 00000 n 0000006090 00000 n 0000007326 00000 n 0000008615 00000 n 0000009016 00000 n 0000009154 00000 n 0000009183 00000 n 0000010495 00000 n 0000011773 00000 n 0000012981 00000 n 0000014002 00000 n 0000015048 00000 n 0000016118 00000 n 0000016189 00000 n 0000076439 00000 n 0000076703 00000 n 0000077175 00000 n 0000077338 00000 n 0 … btype/Link>> endobj 6459 0 obj > endobj 6460 0 obj >stream Microsoft® Word 2010 application/pdf Matt Cope Microsoft® Word 2010 2018-10-25T18:10:56+02:00 2020-12-01T12:40:39+01:00 2020-12-01T12:40:39+01:00 uuid:4DC3B427-F1DE-4141-90FF-148BB005A785 uuid:4fbb2c95-0e1b-ed48-a898-da46d3fb5f41 1 A endstream endobj 6461 0 obj >stream x���wTT��Ͻwz��0tz�R� �WQf�� � "*QD�)� EbE Q{@���Ql�dF�J|yy�����=��g�s��{ߵ.$/?./ � �'�{��#����~ 4�$ v��999&\�D\���? ���x������Cw�$
Pharming announces public cash offer to the shareholders of Abliva AB | Pharming Skip to main content Our news Careers Contact us Our company Rare community Advancing rare care Life at Pharming Investors Home Our news Pharming announces public cash offer to the shareholders of Abliva AB Financial results December 15, 2024 Pharming announces public cash offer to the shareholders of Abliva AB Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysi … nsaction value of approximately US$66.1 million No external funding required to fund acquisition and KL1333 development costs Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST) ( view live webcast ) Pharming Group N.V. today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies B.V.,
%PDF-1.5 %���� 401 0 obj > endobj 423 0 obj >/Filter/FlateDecode/ID[ ]/Index[401 35]/Info 400 0 R/Length 111/Prev 1819844/Root 402 0 R/Size 436/Type/XRef/W[1 3 1]>>stream h�bbd```b``�� i ��D�d��׃E$@$W��"yv�H�20�"98�꿃E��Ȫ ��`�H ɨb3�ma_ �e��_�����Q�F2�� ��� ��Q endstream endobj startxref 0 %%EOF 435 0 obj >stream h��V�Oe��^Gi�2Z �cِ�q !�R�,�n���/��j���YHh�[1T�,$�7��e� �(v[fm�����&�i�}���;� �M���{���� p�.7B��QJÝ�t�T��`�'_^Y1�)tZ��zM`5�Рiʶ��+�]� � �Φ�9�݂�(�D��rz�2��;'u[�/[�i}Ơ�9*�� r4��*��s@��ur����w� ��}CH����t��`&�WT���?��6���y)xH�m8�&�E�a� … T� 5�T�Bh��ex� w��� ��$� ��fg � �� 0�O�+ endstream endobj 420 0 obj >stream application/postscript NeuroVive_Original_CMYK Johan Adobe Illustrator CS2 2008-06-27T08:07:57+02:00 2008-07-03T14:47:06+02:00 2008-07-03T14:47:06+02:00 uuid:5F1646630F44DD119AB7891F60E2B7B5 uuid:0A741D9BE448DD11A484EA40C63A6649 uuid:81F98C94FB40DD118C59F2541EC583A9 uuid:80F98C94FB40DD118C59F2541EC583A9 endstream endobj 421 0 obj >stream Adobe Illustrator(R) 8.0 2030-08-04T00:00Z (.) (F&B) (EP … ���� p�8�ė���"�ށ�>�y�z�/�b�" ��8�b�C���H�>9B>�b� aD� 07I } z#���ۑM >stream application/pdf Utskrift 2014-02-03T14:40:55+01:00 2014-02-03T14:40:55+01:00 2013-12-09T13:41:05+01:00 Adobe Illustrator CC (Macintosh) uuid:b69e6e32-a24e-e344-8098-52a734d6ba64 xmp.did:87a607f1-e219-4bc5-9908-cde72cfa1ac3 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:1ab0e03a-e609-46ee-8331-1b9d7ba214c9 xmp.did:2d91dac9-ef7e-0245-9c25-3fa54e31215b uuid:5D20892493BFDB11914A8590D31508C8 proo … GB PROCESS 130 54 140 Adobe PDF library 10.01 endstream endobj 33 0 obj >stream application/pdf Utskrift 2014-02-03T14:40:55+01:00 2014-02-03T14:40:55+01:00 2013-12-09T13:41:05+01:00 Adobe Illustrator CC (Macintosh) uuid:b69e6e32-a24e-e344-8098-52a734d6ba64 xmp.did:87a607f1-e219-4bc5-9908-cde72cfa1ac3 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:1ab0e03a-e609-46ee-8331-1b9d7ba214c9 xmp.did:2d91dac9-ef7e-0245-9c25-3fa54e31215b uuid:5D20892493BFDB11914A8590D31508C8 proo … 11T12:07:49+01:00 Adobe Photoshop CC (Macintosh) / converted from image/jpeg to application/vnd.adobe.photoshop derived converted from image/jpeg to application/vnd.adobe.photoshop saved xmp.iid:f3438a7f-0ddc-4649-9d15-a755ff1aab9b 2013-12-11T12:07:49+01:00 Adobe Photoshop CC (Macintosh) / saved xmp.iid:09f8673a-5d55-4f46-be16-4214b83b01c8 2013-1
Press releases – Abliva Skip to content Abliva Delivering mitochondrial health English English Svenska Abliva This is Abliva Delivering mitochondrial health Orphan Drugs Relevant publications Mitochondrial Disease Primary mitochondrial disease MELAS-MIDD and KSS-CPEO Leigh Syndrome LHON Patients Expanded access policy Research & Development Portfolio KL1333 NV354 Early programs Clinical trials The FALCON Study Contact Privacy policy Search Search Press releases 2023 All 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 All MAR Regulatory 17 November, 20 … ue reading 4 May, 2023 Regulatory Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023 The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee’s proposal for the election of Board members was [&h ... Continue reading 4 April, 2023 Regulatory Notice of Annual General Meeting of Abliva AB (publ) The shareholders of Abliva AB (publ), corporate
Report – Abliva Skip to content Abliva Delivering mitochondrial health English English Svenska Abliva This is Abliva Delivering mitochondrial health Orphan Drugs Relevant publications Mitochondrial Disease Primary mitochondrial disease MELAS-MIDD and KSS-CPEO Leigh Syndrome LHON Patients Expanded access policy Research & Development Portfolio KL1333 NV354 Early programs Clinical trials The FALCON Study Contact Privacy policy Search Search Press releases Choose year All 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 All MAR Regulatory 21 February, 202